13:28 , Dec 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer's disease (AD) In vitro and mouse studies identified an inhibitor of Aβ 42 polymerization that could help treat AD. In vitro screening of nine amyloid-binding compounds in polymerization assays, followed by in vitro...
22:27 , Nov 6, 2018 |  BioCentury  |  Finance

Advancing AlzeCure

Stockholm-based AlzeCure Pharma AB is planning to raise SEK200 million ($22 million) in an IPO on NASDAQ First North Premier to bring both arms of its Alzheimer’s disease portfolio to the clinic. In a prospectus...
17:50 , May 16, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) In vitro and mouse studies suggest a peptide-based agent that captures Aβ 42 and induces autophagy could help treat AD. The “nanosweeper” agent consists of a PEGylated GKLVFF peptide that binds...
22:03 , May 10, 2018 |  BC Extra  |  Preclinical News

‘Nanosweepers’ could degrade beta amyloid to treat Alzheimer’s

Researchers at Beijing’s National Center for Nanoscience and Technology and colleagues published a paper in Nature Communications describing a self-destructive "nanosweeper" based on multifunctional peptide-polymers that improved memory deficits after capturing and degrading extracellular deposits...
17:36 , May 4, 2018 |  BC Week In Review  |  Clinical News

Merck's verubecestat reduces beta amyloid levels but fails to improve cognition, function

Data published in the New England Journal of Medicine from the discontinued Phase II/III EPOCH trial in 1,958 patients with mild to moderate Alzheimer's disease showed that verubecestat (MK-8931) from Merck & Co. Inc. (NYSE:MRK)...
17:11 , Feb 6, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens; biomarkers

TECHNOLOGY: Cell-free assays; plasma markers A composite measure of Aβ 40 , Aβ 42 and APP 669-711 levels in plasma that determines the brain burden of β amyloid could help stratify AD and MCI patients...
22:50 , Feb 2, 2018 |  BC Extra  |  Preclinical News

Plasma biomarker may aid AD diagnosis

In a study published in Nature , Japanese researchers identified a plasma biomarker of brain beta amyloid burden that had an accuracy of about 90% compared against PET imaging, offering the possibility of cheaper and...
20:54 , Dec 19, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer's disease (AD) Mouse studies suggest antisense oligonucleotides (ASOs) targeting the APOE variant APOE4 could help treat AD. In a mouse model of AD, intracerebroventricular injection of an ASO targeting APOE4 decreased β amyloid...
15:34 , Apr 26, 2017 |  BC Extra  |  Clinical News

Alzheon identifies MOA for AD candidate

In a paper published in CNS Drugs , researchers from Alzheon Inc. (Framingham, Mass.) identified the mechanism of action for tramiprosate, the active agent in its Alzheimer's disease candidate ALZ-801 . The paper showed that...
02:31 , Mar 4, 2017 |  BioCentury  |  Product Development

Diagnosing AD trials

A battery of expensive late-stage failures has made it obvious to Alzheimer’s disease companies that more and better diagnostics will be essential to get new disease-modifying therapies to patients. But so far, the approaches being...